553 related articles for article (PubMed ID: 27550397)
21. Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data.
Gottlieb AB; Deodhar A; Mcinnes IB; Baraliakos X; Reich K; Schreiber S; Bao W; Marfo K; Richards HB; Pricop L; Shete A; Trivedi V; Keefe D; Papavassilis CC; Jagiello P; Papanastasiou P; Mease PJ; Lebwohl M
Acta Derm Venereol; 2022 Apr; 102():adv00698. PubMed ID: 35146532
[TBL] [Abstract][Full Text] [Related]
22. Secukinumab: A Review in Ankylosing Spondylitis.
Blair HA; Dhillon S
Drugs; 2016 Jul; 76(10):1023-30. PubMed ID: 27255593
[TBL] [Abstract][Full Text] [Related]
23. Treating to Target(s) With Interleukin-17 Inhibitors.
Lynde CW; Beecker J; Dutz J; Flanagan C; Guenther LC; Gulliver W; Papp K; Rahman P; Sholter D; Searles GE
J Cutan Med Surg; 2019; 23(2_suppl):3S-34S. PubMed ID: 30742778
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Anti-Interleukin-17A Monoclonal Antibody Secukinumab in Treatment of Ankylosing Spondylitis: A Meta-Analysis.
Katsevman GA; Mariscal G; Barrios C; Domenech-Fernández P; Ziembinski C; Bhatia S
Monoclon Antib Immunodiagn Immunother; 2020 Oct; 39(5):160-166. PubMed ID: 33001775
[TBL] [Abstract][Full Text] [Related]
25. Secukinumab for treating plaque psoriasis.
Rothstein B; Gottlieb A
Expert Opin Biol Ther; 2016; 16(1):119-28. PubMed ID: 26577956
[TBL] [Abstract][Full Text] [Related]
26. Secukinumab (AIN-457) for the treatment of Psoriasis.
Jaleel T; Elmets C; Weinkle A; Kassira S; Elewski B
Expert Rev Clin Pharmacol; 2016; 9(2):187-202. PubMed ID: 26647300
[TBL] [Abstract][Full Text] [Related]
27. In brief: new indications for secukinumab (Cosentyx).
Med Lett Drugs Ther; 2016 Jun; 58(1496):76. PubMed ID: 27249098
[No Abstract] [Full Text] [Related]
28. Clinical efficacy and safety of anti-IL-17 agents for the treatment of patients with psoriasis.
Chen Y; Qian T; Zhang D; Yan H; Hao F
Immunotherapy; 2015; 7(9):1023-37. PubMed ID: 26055639
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.
Imafuku S; Honma M; Okubo Y; Komine M; Ohtsuki M; Morita A; Seko N; Kawashima N; Ito S; Shima T; Nakagawa H
J Dermatol; 2016 Sep; 43(9):1011-7. PubMed ID: 26919410
[TBL] [Abstract][Full Text] [Related]
30. Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis.
Wendling D; Verhoeven F; Prati C
Expert Opin Biol Ther; 2019 Jan; 19(1):55-64. PubMed ID: 30500270
[TBL] [Abstract][Full Text] [Related]
31. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.
Mease P; van der Heijde D; Landewé R; Mpofu S; Rahman P; Tahir H; Singhal A; Boettcher E; Navarra S; Meiser K; Readie A; Pricop L; Abrams K
Ann Rheum Dis; 2018 Jun; 77(6):890-897. PubMed ID: 29550766
[TBL] [Abstract][Full Text] [Related]
32. Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease.
Reich K; Warren RB; Coates LC; Di Comite G
J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1161-1173. PubMed ID: 31785165
[TBL] [Abstract][Full Text] [Related]
33. Secukinumab: A New Treatment Option for Psoriatic Arthritis.
Mease P; McInnes IB
Rheumatol Ther; 2016 Jun; 3(1):5-29. PubMed ID: 27747518
[TBL] [Abstract][Full Text] [Related]
34. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
Boyce EG; Halilovic J; Stan-Ugbene O
Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
[TBL] [Abstract][Full Text] [Related]
35. Safety of secukinumab for the treatment of active ankylosing spondylitis.
Loricera J; Galíndez-Aguirregoikoa E; Blanco R
Expert Opin Drug Saf; 2021 Jun; 20(6):627-634. PubMed ID: 33470130
[No Abstract] [Full Text] [Related]
36. The role of secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis.
Garcia-Montoya L; Marzo-Ortega H
Ther Adv Musculoskelet Dis; 2018 Sep; 10(9):169-180. PubMed ID: 30210583
[TBL] [Abstract][Full Text] [Related]
37. The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond.
Dubash S; Bridgewood C; McGonagle D; Marzo-Ortega H
Expert Rev Clin Immunol; 2019 Feb; 15(2):123-134. PubMed ID: 30576610
[TBL] [Abstract][Full Text] [Related]
38. Treatment of psoriatic arthritis with secukinumab: a case series.
Nicola S; Rolla G; Monti R; Brussino L
J Dermatolog Treat; 2018; 29(sup1):6-8. PubMed ID: 30247936
[TBL] [Abstract][Full Text] [Related]
39. Real-world treatment patterns and use of adjunctive pain and anti-inflammatory medications among patients with psoriatic arthritis treated with IL-17A inhibitors in the United States.
Pizzicato LN; Vadhariya A; Birt J; Ketkar AG; Bolce R; Grabner M; Pepe RS; Walsh JA
J Manag Care Spec Pharm; 2023 Jan; 29(1):24-35. PubMed ID: 36318701
[No Abstract] [Full Text] [Related]
40. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis.
Mease PJ; Armstrong AW
Drugs; 2014 Mar; 74(4):423-41. PubMed ID: 24566842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
